Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 plus nab-docetaxel in previously treated EGFR-high squamous NSCLC
CTR20240822Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug, docetaxel in Pulmonary squamous cell carcinoma, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Mar 2024; status: active.
02
Drugs
becotatugdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20240822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240822.